NeuroOne Medical Technologies (NASDAQ:NMTC) Stock Price Down 5.8% – Here’s Why

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) dropped 5.8% on Monday . The stock traded as low as $0.94 and last traded at $0.97. Approximately 128,628 shares were traded during trading, a decline of 19% from the average daily volume of 158,317 shares. The stock had previously closed at $1.03.

NeuroOne Medical Technologies Stock Down 5.9 %

The company has a market capitalization of $27.16 million, a P/E ratio of -3.38 and a beta of 0.48. The company has a 50 day simple moving average of $1.08 and a two-hundred day simple moving average of $0.94.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Wednesday, February 12th. The company reported $0.06 earnings per share for the quarter. NeuroOne Medical Technologies had a negative return on equity of 270.70% and a negative net margin of 82.17%.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in NeuroOne Medical Technologies during the 4th quarter valued at about $33,000. Geode Capital Management LLC boosted its position in shares of NeuroOne Medical Technologies by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 311,659 shares of the company’s stock valued at $257,000 after buying an additional 27,804 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of NeuroOne Medical Technologies during the third quarter valued at approximately $26,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.